Ning T, Li D, Deng T, Bai Y, et al. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. Cancer 2024 May 23. doi: 10.1002/cncr.35377.
PMID: 38781433